Press Release: STADA welcomes Ingo Schachel as Head of Investor Relations
One document
more
Stories from Bad
- Language:
- Media:
- Period:
- Period:Total
Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar
EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...
morePress release: STADA continues strong growth journey in the first half of 2024
One documentmorePress release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
One documentmorePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmorePress release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...
One documentmorePress release: STADA continues with double-digit sales and profit growth in 2023
One documentmorePress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
One documentmorePress release: Zuellig Pharma becomes STADA Philippines’ exclusive distribution partner
One documentmore- 3
Press release: STADA further improves Sustainability ranking; rates among top 6% of pharma players globally
One documentmore Press release: STADA strikes partnership with CR Sanjiu in China to drive growth of its cough and cold portfolio
One documentmore- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore - 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
One documentmore Press release : STADA further grows its European Consumer Healthcare portfolio by acquiring several additional brands from Sanofi
One documentmorePress release: STADA appoints Christos Gallis as Head of Eastern Europe
One documentmoreProtecting eMobility and EV Charging Infrastructure from Cybersecurity Attacks
morePress release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
One documentmorePress release: STADA sustains strong momentum with double-digit sales and profit growth in 2022
One documentmorePress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
One documentmorePress release: Adalvo and STADA extend their strategic partnership
Adalvo and STADA extend their strategic partnership - Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes - Adalvo CEO Anil Okay: “These new agreements demonstrate the significance of the strategic partnership we have built with STADA, in the last couple of years. We take ...
One documentmorePress release: STADA appoints Boris Döbler as Chief Financial Officer
One documentmoreFresenius Medical Care AG & Co. KGaA
Fresenius Medical Care to acquire NxStage Medical, Inc. to strengthen its vertically integrated dialysis business
Bad Homburg (ots) - Acquisition of NxStage Medical, Inc. would: - position Fresenius Medical Care as a global leader in home dialysis - establish U.S. presence in the critical care space - further enhance clinical outcomes and patient empowerment - support strategic initiative of vertical integration and Care ...
moreNew UK sales subsidiary for Dr. Hauschka: WALA UK Ltd.
Bad Boll/Eckwälden (ots) - Dr. Hauschka, a brand marketed by the traditional German company WALA Heilmittel GmbH, is now able to boost its presence on the UK market. A newly established subsidiary, WALA UK Ltd., which is based in Oxfordshire near London, will be marketing and distributing the premium natural and organic cosmetics products as of 1 January. Dr. Hauschka enthusiasts will be able to find a wide range of ...
moreTop location in Milan - Dr. Hauschka flagship store opens its doors (BILD)
moreEANS-Tip Announcement: Syzygy AG / Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG (the German Securities Act) with the objective of Europe-wide distribution
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
moreEANS-Voting Rights: Syzygy AG / Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
moreEANS-Voting Rights: Syzygy AG / Correction of a release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution from Feb 15, 2012 at 15:16
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
moreEANS-Voting Rights: Syzygy AG / Correction of a release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution from Jan 16, 2013 at 09:24
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
moreEANS-Voting Rights: Syzygy AG / Release according to article 26, section 1 WpHG (Securities Trading Act) with the aim of Europe-wide distribution
issuer: Syzygy AG Im Atzelnest 3 D-61352 Bad Homburg phone: +49(0)6172 9488-100 FAX: +49(0)6172 9488-272 mail: ir@syzygy.net WWW: http://www.syzygy.net sector: Online ISIN: DE0005104806 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart, ...
more
12Next